Saturday, July 11, 2009

P53 Mutation Most Common in Women with Hormone-Negative Breast Cancer

Researchers say that nearly 26 percent of women with breast cancer have a mutation in the p53 gene, which repairs damage to the DNA.  And it’s most prevalent among premenopausal women with ER-/PR- breast cancer and in postmenopausal hormone-negative women with a high body mass index (BMI).  The latter group had higher-grade tumors and a poorer outcome.  High BMI is already considered a risk factor for breast cancer.

The study included 1,170 women diagnosed with breast cancer between 1996 and 2001 and 2,116 women without cancer, and was designed to look at how lifestyle and environmental factors affect breast cancer.

 "The p53 gene is the guardian of the genome because it signals the cell to repair DNA damage when that occurs. If we can find genetic or environmental risk factors that lead to damage of p53 or stress on the gene, we may be able to help prevent development of breast cancer as well as other cancers," says the study's lead investigator, Catalin Marian, MD, PhD, a research instructor of cancer genetics and epidemiology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC)
The research was presented at the 2009 annual meeting of the American Association for Cancer Research.  Read more here. 

New Gene May Provide Key to Basal Breast Cancer

Many triple-negative breast cancer tumors are basal, and these are the most aggressive.  Researchers have isolated a gene—the Met gene—that is in the majority of breast cancers.  More aggressive forms of cancer—basal types—have more of the gene.  There are existing inhibitors for this gene, so  scientists say this study may lead to new treatment for triple negative and other hormone negative forms.  Researchers were associated with the Van Andel Research Institute in Grand Rapids, Michigan, headed by George Vande Woude, Ph.D., who has been studying the Met gene since the 1980s.


"This very exciting work by the Van Andel Research Institute gives us a new target for treatment of patients with one of the worst types of breast cancer — basal breast cancer," said Dr. Daniel D.  Von Hoff, Physician-in Chief of the Translational Genomic Research Institute (TGen) in Phoenix, Arizona, which initiated an alliance with Van Andel Institute in February. "Since there are many new inhibitors of Met available for clinical trials, we now have a direct route for immediate application of these important findings in the care of patients with this very aggressive form of breast cancer."

Read more here.

 

 

 

Tuesday, July 7, 2009

Vitamin A May Lead to Drug for Triple Negative

Retinoic acid, a component of Vitamin A, has the potential to treat breast cancer, including triple negative, according to research in the June 24, 2009 issue of the journal Cell.

The main story being reported is on retinoic acid’s influence on hormone-positive breast cancer, helping the body balance the effect of hormones.  Here’s how it goes: estrogen makes cells grow rapidly; retinoic acid slows that process down.  And that's an important story.

But researchers say retinoic acid can even help cancers that are not fueled by estrogen—that is, hormone-negative cancers such as triple negative.  And that's a bigger story, because at this point triple negative breast cancer has no drug therapy, as the primary breast cancer drugs, tamoxifen and Arimidex, are designed to combat estrogen, which is not a factor in estrogen-negative cancer.

From a news release from the University of Chicago, whose scientists conducted the research: 

"Understanding all the components of this process could be used against breast cancer care in three ways," said study leader, Kevin White, PhD, professor of human genetics and director of the Institute for Genomics and System Biology at the University of Chicago. "It suggests new ways to think about preventing the disease in those at high risk. It offers molecular tools that could provide a more precise diagnosis and predict outcomes. It could also be used to enhance current therapies, making existing drugs, such as tamoxifen, that selectively block estrogen's effects even more powerful, or even to develop new anti-cancer drugs."

White's team studies the effects of nuclear receptors, a class of proteins found within cells that control the response to various hormones. When a hormone enters a cell and connects with its receptor, that receptor alters the pattern of expression of specific genes--often hundreds or more.

But, they note, cancers that do not respond to hormones can also be affected.

This competition between the two signals also provides a new tool to predict outcomes. The researchers compared the effects of retinoic acid on tissues from 295 breast cancer patients against the results from their initial study using a typical breast cancer cell line. They found that the more responsive a tumor was to retinoic acid, the better the odds of long-term relapse-free survival.

Some of the genes that respond to retinoic acid were expressed even in difficult-to-treat tumors, such as those that do not have estrogen receptors or the molecule targeted by the drug Herceptin, the so-called double- or triple-negative breast cancers. "Some of these genes may provide new drug targets," White said.

Although retinoic acid is approved for treatment of leukemia, it can be quite toxic and patients can develop resistance to the drug. This study suggests a long series of downstream targets that are activated by the RA receptor.

"The goal would be to develop drugs that could activate these cancer-inhibiting targets," said White. “Retinoic acid itself is probably not the solution because of its side effects and metabolic byproducts," He cautioned, "but our results provide a molecular justification for finding ways to overcome its limitations in the clinic.”

 

 

 

 

Wednesday, June 24, 2009

PARP Inhibitors May Help More Than Triple Negative

I’ve written about PARP inhibitors recently, but they’re back in the news. 

Patients with cancer genes—BRCA1 and BRCA2—have been shown to react positively to a type of PARP inhibitor, a drug called olaparib.  In a small but significant study, olaparib was successful in shrinking breast and prostate cancer tumors, with some disappearing entirely.  The study was reported in the New England Journal of Medicine.

Read more about it here.

PARP is short for poly (ADP-ribose) polymerase, an enzyme used by cancer cells to repair DNA damage.

 


 

Friday, June 19, 2009

Herceptin May Be Effective Drug for Hormone Negative Breast Cancer

The drug commonly used for Her2-positive breast cancers may actually turn ER-negative status into positive. It’s a two-step process, though, and the research was done on ER-negative, Her2-positive laboratory cells, not on human subjects.  Still, it offers amazing potential and could ultimately provide much-needed therapy for hormone-negative breast cancer, including triple negative.

After being treated with trastuzumab (Herceptin), ER-negative cells actually turned into ER-positive cells, making them then react to anti-estrogen drugs like tamoxifen and aromatase inhibitors, according to research presented at the Endocrine Society meeting this month.

The research was done in vitro—in a lab, on existing cells, rather than in human subjects. Cells were ER-negative, Her2-postive and  were treated with  trastuzumab; after 72 hours they were treated with the hormones estradiol  and androstenedione.  After that they were given aromatase inhibitors and antiestrogens.

The tumors then reacted in much the way ER-positive tumors do to aromatase inhibitors and antiestrogens.

Read more about the study here.

SOURCE: Sabnis G, Brodie A "Trastuzumab sensitizes ER negative, HER-2 positive breast cancer cells (SKBr-3) to endocrine therapy" ENDO 2009; Abstract OR38-02.

Monday, June 15, 2009

Oral Contraceptives Increase the Risk of Triple Negative Breast Cancer

Women under the age of 40 who used oral contraceptives increase their risk of triple-negative breast cancer by more than 2.5 times, according to research in Cancer Epidemiology Biomarkers and Prevention (April, 2009).   There was no increase in the risk for hormone-positive breast cancer.

 

 


Sunday, June 14, 2009

Scientists study protein linked to triple negative

The protein EZH2 is found in a great majority (74 percent) of hormone-receptor-negative tumors, mostly in triple negative. It is linked to larger tumor size—over 2 cm—and affected lymph nodes, according to research presented at the 2009 annual meeting of the American Society of Clinical Oncology.

Researchers speculate that EZH2 could ultimately be much-needed therapy for women with hormone-negative breast cancer. The study is continuing with the goal of determining EZH2's role in survival of hormone-negative cancer.

Tuesday, June 9, 2009

More perspective on PARP inhibitors for triple negative

An expansion on my previous post on PARP inhibitors:

A Curetoday.com blog gives a bit more explanation on the recent research (presented at the American Society of Clinical Oncology annual meeting)  showing how PARP inhibitors can help advanced triple negative breast cancers:

What happens when a preliminary study that was not designed for drug approval ends up showing dramatic results?

A study in patients with advanced "triple negative" breast cancer (defined as being negative for estrogen, progesterone, and HER2 receptors) compared chemotherapy (Gemzar and carboplatin) with or without BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor.

PARP inhibitors have been shown to work exceptionally well in the laboratory against cancers that have defects in DNA repair – this is an abnormality that is prominent in cancers that derive from patients who have inherited mutations in the breast and ovarian cancer predisposing genes BRCA1 and 2. It turns out that BRCA1-associated tumors tend to be triple negative (although not all triple negative tumors have abnormalities of the BRCA pathways).

This was a preliminary phase II study, so even though it was randomized, it did not have enough patients to qualify as an FDA-approval trial. But it nevertheless showed unprecedented effects on inducing tumor responses, delaying time to progression, and improving survival – even greater than hormonal therapy and Herceptin have.

Read the entire article here.

Sunday, June 7, 2009

Two stories of women coping with triple negative


“We’re a package deal.”

That’s how Heather Gideon describes her relationship with Angie Huxtable.

So when Huxtable agreed to be in today’s style show for the annual Cattlemen’s Ball of Nebraska, Gideon said, there was absolutely no question she would appear on the runway as well.
The style show is just one of the many activities that will help raise money for cancer research as part of the 2009 
Cattlemen’s Ball, which has a goal of collecting $1 million.
Whatever amount is raised will go to the UNMC Eppley Cancer Center and local health care organizations.

That money for research is important to both Wood River women, who were each diagnosed with breast cancer in May 2007.

While Huxtable remains cancer free, Gideon’s cancer re-emerged just months after her initial round of treatment was finished. Gideon is now diagnosed with Stage 4 breast cancer.

“I’ve been given one to four years to live,” said Gideon, who noted there is no current treatment that doctors say will cure her cancer.

Treatments now are designed to hold the cancer at bay.

Another Triple Negative Survivor Story


Hope and healing are often found in the unlikeliest of places. Breast cancer survivor Candy Reid found source of hope in a circle of tubing better known as the hula hoop.

Reid is the founder of Hoops for Healing, a online business that sell hula hoops custom made by Reid and her family.

She said that she cannot believe how the business has taken off and that the journey from battling cancer to operating a successful business was as circular as the hoops she now makes from her home in Albany.

"What came from this horrible experience is amazing to me," said Reid. "I've grown a lot, I've changed a lot. God has really been able to show his goodness through so many ways."

She said that before hearing the terrible news that she had breast cancer in December 2007, she was a busy housewife dedicated to home schooling her four children.

"I am really dedicated to my family and they have been so supportive through all this," Reid said.

She said that she was diagnosed with triple negative breast cancer, a specific subtype of cancer that is clinically characterized as more aggressive and less responsive to standard cancer treatments.

"I immediately began chemotherapy treatments which ended in May 2008 and then I had a bilateral mastectomy in June 2008," Reid explained. "This was followed by seven weeks of radiation."

Saturday, June 6, 2009

Your Nurse Can be Your Advocate

In the confusing days and weeks after a breast cancer diagnosis, a nurse navigator or patient advocate can help you make sense of your disease and its treatment and even guide you in getting a second option.  Nurse navigators follow cancer patients from diagnosis through follow-up care and help make sense of the doctors, treatments, jargon, and options while providing a supportive presence.  In most cases, navigators collaborate with all members of the medical team; educate and counsel patients and their families; and coordinate care with oncologists, surgeons, pharmacists, dieticians, and counselors. 

Check to see if your healthcare provider offers access to such a professional.  If not, lobby for them to start.  We all need more information than we have after a breast cancer diagnosis.  We should not be left to our own devices to figure it all out.

 

Cancer-Fighters in Your Kitchen

Stock your cupboards and fridge with tasty cancer fighters. A diet rich in fruits and vegetables and low in fat is the recipe for breast health, according to numerous studies:

• Whole grain breads and cereals fortified with B vitamins, especially folate. Folate is important in fighting hormone-negative breast cancer.

• Cruciferous vegetables: broccoli, cauliflower, cabbage, kale. These are high in Indole-3-Carbonale (I3C) that has been shown to have anti-cancer properties.

• Fruits and vegetables, especially brightly colored. Red and purple plants—red cherries, blueberries, acai—are high in anthocyanins, which are potent antioxidants.

•  Green tea, which contains plant chemicals called catechins, a plant chemical that may inhibit the invading capacity of breast cancer cells.

•  Flaxseeds, which contain cancer-fighting lignans.

• Organic foods when possible, especially dairy products. Organic food is grown or produced without the use of pesticides, fertilizers, antibiotics or growth hormones, all of which are implicated in breast cancer.

It’s Not a One-Size-Fits-All Disease: Breast Cancer Myths

MYTH 1:  Breast cancer is always fatal. fact: The great majority of women with breast cancer go on to live long and meaningful lives.  Ninety-three percent of the women with the most common type, hormone-positive, are disease-free at five years.  

MYTH 2:  There’s always a tumor. FACT:  two types—lobular and inflammatory—may have no lumps.  Women with lobular often have thickening of the breasts; those with inflammatory usually have red, swollen breasts, often with a pitted appearance.  

MYTH 3:  Estrogen is always the culprit. FACT: there’s a form of breast cancer that most often strikes young women, that is not fueled by estrogen.

MYTH 4:  Tamoxifen or Arimidex are for everybody.  FACT: women with estrogen-negative disease get no benefit from these drugs, which are estrogen blockers.   This is especially important, as these drugs have significant side effects, one of which is an increased risk of other cancers.

A Weight-Loss Strategy That Works: Your Friends

OK, so you know losing weight can improve your chances of fighting cancer, but how can you focus on weight loss when you’re fighting for your life after a cancer diagnosis?   Ask friends to help. Research (New England Journal of Medicine, July 2007) shows that we lose weight more effectively if we belong to a social network in which others are also losing. So, when friends and family ask what they can do for you, give them an option that helps their health as well. Work together to change your diet and increase your physical activity.  

• Make a formal diet and exercise plan and publicize it. Going public makes it harder to fall off the wagon.

• Don’t diet—change the way you eat. This is not a short-term goal, but a long-term change. And your family will benefit from a healthier diet as well—you will be helping them reduce their cancer risk.

• Have healthy potlucks. Show off your low-calorie, low-fat, low-cholesterol recipes and show one another that you can still enjoy food together.

• Pool your money to hire a dietician. Most cancer clinics have access to these professionals.
 
• Create your own gym group with a personal trainer.

• Have fun—get a dance video game, round up the kids and boogie the pounds away.

Your Best Way to Fight Breast Cancer: Lose Weight


Maintaining a healthy weight is crucial to avoiding breast cancer, fighting it once you’ve been diagnosed, and reducing its risk of recurrence. Yet most cancer patients are overweight and few know of the relationship between weight and cancer. Some stats:

• Women who gained 55 lbs. or more after age 18 had almost 1½ times the risk of breast cancer compared with those who maintained their weight, [July 12, 2006, issue of the Journal of the American Medical Association.]

• Many doctors reduce the levels of chemotherapy for obese women, potentially hurting their chances of survival, according to research at the University of Rochester Medical Center.

• Breast cancer survivors who ate a low-fat diet—of 32 grams a day, or roughly 20 percent of the daily allotment of fat— lowered their risk of recurrence, in some cases by an impressive 42 percent, according to the Women’s Intervention Nutrition Study (WINS).

• Canadian researchers discovered that breast cancer survivors, for the most part, have a surprisingly unhealthy lifestyle, being obese and low on physical activity. [June 1 2008 issue of Cancer, the journal of the American Cancer Society.]

• A majority of women in a recent study were unaware that being overweight increased their cancer risk. [October 2008, Obstetrics and Gynocology.]

Monday, June 1, 2009

New drug being tested for triple-negative breast cancer

News from the 2009 annual meeting of the American Society of Clinical Oncology:  PARP inhibitors continue to be a promising line of attack for triple negative.  In a study presented at the conference on a new drug, BS-201, which includes a PARP inhibitor:

•  of 116 women with advanced triple-negative breast cancer, those who received the drug in addition to standard chemotherapy lived a median of 9.2 months, compared with 5.7 months for those who received only the chemotherapy. 

• PARP inhibitors block the action of an enzyme that helps repair DNA. Without the ability to repair their DNA, tumor cells can die or more easily be killed by chemo.

• BS-201, was developed by BiPar Sciences  that was acquired in April by Sanofi-Aventis.  AstraZeneca is also developing PARP inhibitors.

Friday, May 22, 2009

African-American Women May Refuse Important Treatments for Triple Negative

One in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, says research to be published in the July 1, 2009 issue of Cancer, a  journal of the American Cancer Society.

Researchers reviewed stage III breast cancer data from 2000 to 2006 from an inner city hospital in Atlanta that serves a large African American population.

They identified 107 cases diagnosed, treated or both from 2000 to 2006. Roughly 87 percent of these cases were in African American women; 29 percent of all cases were triple negative.

• 20.5 percent of patients with stage III breast cancer refused chemotherapy.

• 26.3 percent who should have received chest radiation refused.

• There was no difference in marital status, religious background, or age of the patients who refused either chemotherapy or radiation compared with the patients who received recommended care.

Why did some women refuse care?  Researchers aren’t sure why, but they speculate that a range of factors could be involved:  socioeconomic and demographic factors, cultural beliefs, healthcare access, additional illnesses, and patient choice.  

But here’s the neat part:

As a result of the study, researchers have implemented a community outreach program that includes a nurse practitioner and a social worker who follow all patients throughout their cancer treatments, ensuring that they get proper care.  All women should have this sort of resource, but this is a good beginning.

Source:   “Characteristics and treatment modalities for African American Women diagnosed with Stage III breast cancer.” Monica Rizzo, Mary Jo Lund, Marina Mosunjac, Harvey Bumpers, Leslie Holmes, Ruth O’ Regan, Otis W. Brawley, and Sheryl Gabram. CANCER; Published Online: May 22, 2009 (DOI: 10.1002/cncr.24334); Print Issue Date: July 1, 2009.

Risk factors for triple negative breast cancer

The Life After Cancer Epidemiology (LACE) Study underscores what other research has demonstrated: women with triple negative breast cancer are more likely to:

• be younger at diagnosis
• African American
• overweight and/or obese at diagnosis if premenopausal

The were less likely to breastfeed for long periods—more than four months—and were more likely to not breastfeed if they had at least three children.

The study consisted of 2280 women diagnosed with invasive breast cancer (stages I, II, or IIIA) between 1997 and 2000 and recruited primarily from the Kaiser Permanente Northern California Cancer Registry and the Utah Cancer Registry. They were between 18 and 70 years old and between 11 and 39 months post-diagnosis, free of recurrence, and with no history of other cancers in the five years prior to enrollment.

Tumor subtypes the used and the percentage in that group:

Luminal A: ER positive and/or PR positive, and Her2 negative (73.4%)
Luminal B: ER positive and/or PR positive, and Her2 positive (11.6%)
Triple negative: ER negative, PR negative, and Her2 negative (11.3%)
Her2-overexpressing: ER negative, PR negative, and Her2 positive (3.7%)

Luminal B cases were more likely to be younger at diagnosis and were less likely to consume alcohol or use hormone replacement therapy.

Her2-overexpressing cases were more likely to be younger at diagnosis, less likely to use hormone replacement therapy, and Hispanic or Asian.

Some other interesting stats:

•The majority of the whites (75.3%), Asians (71.4%), Hispanics (68.5%), other (68.5%), and African Americans (59.4%) had luminal A tumors.
• Her2-overexpressing tumors were least common among all races/ethnicities (whites 3.1%, African Americans 3.2%, Asians 6.4%, Hispanics 6.6%, other 5.5%).
• African Americans had the highest prevalence of the triple negative subtype (28.4%) compared with the other races/ethnicities (whites 10.5%, Asians 6.3%, Hispanics 10.7%, other 13.0%).
•African Americans (average age: 56.2) and Asians (average:54.8 years) were more likely to be diagnosed at a younger age.
•Whites were more likely to be diagnosed at an older age (59.8).
•, Asians (59.1%) were less likely to be post-menopausal than whites.
(75.6%), African Americans (71.4%), and other races/ethnicities (72.9%).
• A family history of breast cancer was more common among whites (22.6%) and other
races/ethnicities (24.1%), than among the other groups.
• African Americans and Hispanics had more biological children and were younger during their first pregnancy.
• Whites were more likely to have consumed alcohol while Asians were more likely to have never smoked.
• More whites had used HRT (76.2%).
• Fewer Asians (44.1%) had used oral contraceptives.
• African Americans were more obese at diagnosis.

The study was published in the May 2009 Breast Cancer Research, an open access journal. Download a
PDF here.  Or read the abstract.


SOURCE: Kwan, ML, Kushi, L, Weltzien,E, Maring, B, Kutner, S, Fulton, R, Lee, M,Ambrosone, C, Caan,B,  “Epidemiology of breast cancer subtypes in two prospective cohort studies of
breast cancer survivors,”
Breast Cancer Research, 2009, 11:R31. 

Thursday, May 21, 2009

Bisphosphonate may benefit metastatic hormone negative breast cancers

According to research in the open-access journal,  BMC Cancer, patients with hormone-negative cancer with bone metastases may  benefit from bisphosphonate (BP) treatment.  Of the 317 patients followed, 230 (72.6%) had hormone positive breast cancer and 87 patients (27.4%) had hormone negative.  

Patients with hormone-positive breast cancer showed no benefit from BP.  Those with hormone-negative,  however, showed what researchers called "significant prolonged survival" from the drug. Disease-free survival was more than two years, with fewer than three metastatic sites.  Patients received an average of 17.7 cycles of BP.

Download a PDF of the research here.

New study planned for hormone-negative therapies

Aragon Pharmaceuticals has raised $8 million to discover and develop new therapeutics for the treatment of hormone-negative cancers, with an initial focus on prostate and breast cancer.

The company has been involved in recent discoveries that show that the biology of hormone-negative cancers can be overcome through the creation of a new class of nuclear receptor targeting drugs.

The company will focus on androgen and estrogen receptors.

Read the company's news release here.